Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bringing it All Back Home.

Journal of cardiac failure·2025

Same author

Model for End Stage Liver Disease Excluding International Normalized Ratio Predicts Severe Right Ventricular Failure After HeartMate 3 Implantation in a Contemporary Cohort.

Journal of the American Heart Association·2025

Same author

Predictive Accuracy of HeartMate 3 Risk Score After the Heart Transplant Allocation Change.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2024

Same author

Post-myocardial infarction ventricular septal defect repair via right ventriculotomy with concomitant durable Heartmate 3 implantation after bridging with Impella 5.5.

Artificial organs·2024

Same author

Giant Left Ventricular Aneurysm With Dynamic Right Ventricular Compression and Subsequent End-Stage Heart Failure.

JACC. Case reports·2024

Same author

Escalating Surgical Treatment for Left Ventricular Assist Device Infection and Expected Mortality: Clinical Risk Prediction Score.

Journal of the American College of Surgeons·2024

Search research articles

Related Experiment Video

Updated: Mar 6, 2026

An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse

An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse

Published on: September 12, 2018

Potential Expanded Indications for Neprilysin Inhibitors.

Elizabeth Riddell¹, Justin M Vader²

¹Cardiovascular Division, Washington University School of Medicine, 660 S. Euclid Ave., Box 8086, St Louis, MO, 63110, USA.

Current Heart Failure Reports

|March 11, 2017

Summary

Sacubitril/valsartan, a neprilysin inhibitor, shows promise beyond heart failure. Ongoing trials are exploring its benefits in cardiovascular and non-cardiovascular conditions, including renal and neurological functions.

Keywords:

Cardiovascular disease Heart failure Neprilysin inhibitors Sacubitril/valsartan

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

Related Experiment Videos

Last Updated: Mar 6, 2026

An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse

An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse

Published on: September 12, 2018

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

Area of Science:

Cardiovascular Medicine
Pharmacology

Background:

Neprilysin inhibition is a novel therapeutic strategy.
Sacubitril/valsartan combines neprilysin and renin-angiotensin-aldosterone system (RAAS) inhibition.

Purpose of the Study:

To review potential expanded indications for neprilysin inhibitors.
To examine ongoing and future trials of sacubitril/valsartan in cardiovascular and non-cardiovascular diseases.

Main Methods:

Review of existing literature and ongoing clinical trial designs.
Analysis of mechanistic data from preclinical studies.

Main Results:

Sacubitril/valsartan demonstrated superiority over enalapril in stable heart failure with reduced ejection fraction (NYHA class II-III) in the PARADIGM-HF trial.
Preliminary data suggest potential benefits in acute heart failure, heart failure with preserved ejection fraction, and post-myocardial infarction systolic dysfunction.
Emerging evidence indicates potential impacts on renal and neurological functions.

Conclusions:

Sacubitril/valsartan offers a new therapeutic approach with broad potential.
Further randomized trials are necessary to confirm its efficacy in expanded cardiovascular and non-cardiovascular indications.